Navigation Links
Amgen to Appeal CHMP Opinion on Vectibix® (Panitumumab) Use With Chemotherapy in Metastatic Colorectal Cancer in Europe
Date:3/30/2011

THOUSAND OAKS, Calif., March 30, 2011 /PRNewswire/ -- Amgen (Nasdaq: AMGN) announced today that it has submitted a request to the European Medicines Agency (EMA) for a re-examination of the negative opinion issued in March by the Committee For Medicinal Products for Human Use (CHMP) for the use of Vectibix in combination with chemotherapy for patients with wild-type KRAS metastatic colorectal cancer (mCRC).

Amgen believes that Vectibix in combination with chemotherapy provides an important treatment option for patients with wild-type KRAS mCRC.  Amgen remains committed to patients with this aggressive disease, for whom there are limited treatment options.

Data from studies 20050203 (PRIME) and 20050181 ('181') showed that adding Vectibix to FOLFOX and FOLFIRI chemotherapy, respectively, improved progression-free survival (PFS) versus chemotherapy alone in patients with wild-type KRAS mCRC.  Patients taking this combination have a greater chance of living longer without their disease getting worse.  Additionally, the response rate of Vectibix plus chemotherapy was higher than chemotherapy alone.  Though quantitatively greater, the improvement in median overall survival did not achieve statistical significance in the Vectibix arm of either trial.(i)(ii)

In general, adverse event rates were comparable across arms in both studies, with the exception of known toxicities associated with anti-EGFR therapy, such as rash, diarrhea, and hypomagnesemia. Vectibix-related grade 3/4 infusion reactions were reported in less than one percent of patients. In patients with mutant KRAS tumors, outcomes were inferior for those receiving Vectibix plus FOLFOX versus FOLFOX alone.(iii)(iv)

Vectibix is already approved and established in more than 30 countries outside of the United States (U.S.) as a monotherapy treatment for
'/>"/>

SOURCE Amgen
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Amgen Donates $1 Million to Help Japanese Disaster Victims
2. Amgen Completes Acquisition of BioVex
3. NBPTS and Amgen Foundation Join to Bolster Science Education
4. Amgen to Present at the Citi 2011 Global Healthcare Conference
5. CURE Magazine Teams Up With Amgen Oncology and Breakaway from Cancer® to Launch 2011 Extraordinary Healer Award for Oncology Nursing
6. Boehringer Ingelheim to Purchase Amgens Fremont (USA) Facility
7. Amgen’s Fourth Quarter 2010 Adjusted Earnings Per Share Increased 11 Percent to $1.17; Full Year 2010 Adjusted Earnings Per Share Increased 6 Percent to $5.21
8. Genelux Corporation Expands Board of Directors, Appointing Dennis Fenton, Former Amgen Executive
9. Boehringer Ingelheim to Purchase Amgens Fremont (California) Facility
10. MedImmune In-Licenses Clinical-Stage Anti-Inflammatory Monoclonal Antibody From Amgen
11. Amgen to Present at the 29th Annual JP Morgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... , Sept. 22, 2014  Elusys Therapeutics, Inc. ... treat infectious disease, today announced it has completed ... of obiltoxaximab (ETI-204). Obiltoxaximab is an anti-toxin in ... data from these studies support the safety and ... at the intended therapeutic dose. The conclusion of ...
(Date:9/22/2014)... , Sept. 22, 2014  Continua and ... in healthcare technology, media and telecommunications,  have formed ... China and promote international ... BHG announced this new partnership during the global ... Washington, DC , while also ...
(Date:9/22/2014)... Sept. 22, 2014  Aethlon Medical, Inc. (OTCQB: ... to address infectious disease, cancer and other life-threatening ... Projects Agency (DARPA) has informed the Company that ... with year four of a five-year $5.9 million ... 30, 2011 under DARPA,s Dialysis-Like Therapeutics (DLT) program. ...
Breaking Medicine Technology:Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 2Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 3Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 4Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 5Elusys Announces Results From Three Phase 3 Safety Studies Of Its Anthrax Anti-Toxin, Obiltoxaximab (ETI-204), In Adult Volunteers And Completion Of Its Phase 3 Clinical Development Program 6Continua and Borderless Healthcare Group Form Strategic Partnership, Launch the Healthcare Technology Innovation Center in Shanghai 2Continua and Borderless Healthcare Group Form Strategic Partnership, Launch the Healthcare Technology Innovation Center in Shanghai 3Continua and Borderless Healthcare Group Form Strategic Partnership, Launch the Healthcare Technology Innovation Center in Shanghai 4Aethlon Medical Receives Notice of DARPA Contract Renewal 2Aethlon Medical Receives Notice of DARPA Contract Renewal 3Aethlon Medical Receives Notice of DARPA Contract Renewal 4
... , SALT LAKE CITY, Nov. 27 ... VAR ), a premier supplier of X-ray tubes and ... detectors at the RSNA Annual Meeting in Chicago, Ill. from November ... X-ray tube technology for multiple modalities as well as specialized cancer ...
... , CHICAGO, Nov. 27 ... annual meeting starting Sunday, Royal Philips Electronics ( PHG, AEX: ... informatics solutions designed to directly address the priorities of patients ... a desire for value, modular price points and easy upgradability. ...
Cached Medicine Technology:Varian Medical Systems to Highlight the Latest Digital Detectors, X-ray Tubes and Cancer Treatment Technology at the Radiological Society of North America (RSNA) Annual Meeting in Chicago 2Philips Helps Hospitals Strike Balance Between Innovation and Value 2Philips Helps Hospitals Strike Balance Between Innovation and Value 3Philips Helps Hospitals Strike Balance Between Innovation and Value 4
(Date:9/22/2014)... Hamilton, ON (September 22, 2014) McMaster scientists have ... a new class of antibiotics. , Although dozens ... looked at how a certain part of bacteria are ... stopping it. , The discovery is important as ... is making the cures for infections ineffective. The World ...
(Date:9/22/2014)... 2014 This Flash Report is a ... needs for the Prostate Cancer market. , Download the ... strategies for any launching Prostate Cancer product:, ... an increasingly crowded market , Understanding stakeholder ... identifying community-based thought leaders and stakeholders ,Download the ...
(Date:9/22/2014)... researchers have published a pilot study showing the ... people with multiple sclerosis (MS). Improvements were ... and pain. "Development and effectiveness of a ... Description and outcomes" was epublished ahead of print ... of MS Care (doi: 10.7224/1537-2073.2013-045). The authors ...
(Date:9/22/2014)... New York (PRWEB) September 22, 2014 ... with the use of power morcellators ( http://www.gynecaremorcellatorlawsuit.com/ ... notes a new report detailing the continued use ... from federal regulators that specifically discouraged these procedures. ... believe that the potential cancer risks associated with ...
(Date:9/22/2014)... HealthDay Reporter MONDAY, Sept. ... wonders: What can I do to help ensure a healthy ... prescribed may play a role in reducing the risk of ... researchers found that mothers of children with autism were significantly ... pregnancy than those whose children seem to be developing normally. ...
Breaking Medicine News(10 mins):Health News:Download HeartBeat Experts White Paper: Stakeholder Management for new Prostate Cancer Products 2Health News:Power Morcellator News: Bernstein Liebhard LLP Notes New Report Detailing Continued Use of Uterine Morcellation Despite FDA Warning 2Health News:Power Morcellator News: Bernstein Liebhard LLP Notes New Report Detailing Continued Use of Uterine Morcellation Despite FDA Warning 3Health News:Power Morcellator News: Bernstein Liebhard LLP Notes New Report Detailing Continued Use of Uterine Morcellation Despite FDA Warning 4Health News:Could Low Iron Intake During Pregnancy Raise Autism Risk? 2Health News:Could Low Iron Intake During Pregnancy Raise Autism Risk? 3
... training program designed to increase empathy with their ... their interactions with the residents. This contrasts with ... drops during medical school and residency training. The ... (MGH) researchers will appear in the Journal ...
... immunise against serious pneumococcal disease does not offer full ... University of Gothenburg, Sweden, finding that the number of ... Each year an estimated 1 million children worldwide ... are those in poor countries, but pneumococcal bacteria cause ...
... be an indicator of whether a person is high-risk for ... of Colorado School of Medicine, shows people with blue eyes ... to scientists, that people with brown eyes may be less ... in which pigment loss results in irregular white patches of ...
... , FRIDAY, May 4 (HealthDay News) -- Thermography -- a ... for mammography -- is an unreliable cancer screen, according to ... thermography missed about 50 percent of cancers and delivered too ... Bryn Mawr Hospital in Pennsylvania. The radiation-free screening method ...
... News) -- Obese drivers are less likely than normal-weight drivers ... Researchers from the University at Buffalo, in New York, analyzed ... normal-weight drivers were 67 percent more likely to wear a ... a body-mass index (BMI) of 40 or higher is considered ...
... -- Patients with mental health emergencies wait an average of ... emergency departments, and those who are older, uninsured or intoxicated ... with psychiatric emergencies wait about 42 percent longer in the ... online May 1 in the Annals of Emergency Medicine ...
Cached Medicine News:Health News:Brief training program improves resident physicians' empathy with patients 2Health News:Brief training program improves resident physicians' empathy with patients 3Health News:Pneumococcal disease: More cases but fewer deaths 2Health News:Eye color may indicate risk for serious skin conditions 2Health News:Mammograms Beat Thermography for Breast Cancer Detection: Study 2Health News:Mammograms Beat Thermography for Breast Cancer Detection: Study 3Health News:Obese Drivers Less Likely to Buckle Up: Study 2Health News:Psychiatric Patients Often Wait Nearly 12 Hours in ER 2
The Optima III 45 cm line of laparoscopic hand instruments is ideal for operative laparoscopic/endoscopic procedures or when a longer instrument is needed....
The Optima III 45 cm line of laparoscopic hand instruments is ideal for operative laparoscopic/endoscopic procedures or when a longer instrument is needed....
The Optima III line of laparoscopic hand instruments provides a well-crafted set of instruments designed for strength and durability....
The Optima III line of laparoscopic hand instruments provides a well-crafted set of instruments designed for strength and durability....
Medicine Products: